Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Rhomberg, W; Wink, A; Pokrajac, B; Eiter, H; Hackl, A; Pakisch, B; Ginestet, A; Lukas, P; Potter, R.
Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation.
Int J Radiat Oncol Biol Phys. 2009; 74(1):187-191
Doi: 10.1016/j.ijrobp.2008.06.1492
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hackl Arnulf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: In previous studies, razoxane and vindesine together with radiotherapy was proved to be effective in soft tissue sarcomas (STS). Because razoxane leads to a redifferentiation of pathological tumor blood vessels, it was of particular interest to study the influence of this drug combination in vascular soft tissue sarcomas. METHODS AND MATERIALS: This open multicenter Phase II study was performed by the Austrian Society of Radiooncology. Among 13 evaluable patients (10 angiosarcomas and 3 hemangio-pericytomas), 9 had unresectable measurable disease, 3 showed microscopic residuals, and 1 had a resection with clear margins. They received a basic treatment with razoxane and vindesine supported by radiation therapy. Outcome measures were objective response rates, survival time, and the incidence of distant metastases. RESULTS: In nine patients with measurable vascular soft tissue sarcomas (eight angiosarcomas and one hemangiopericytoma), 6 complete remissions, 2 partial remissions, and 1 minor remission were achieved, corresponding to a major response rate of 89%. A maintenance therapy with razoxane and vindesine of 1 year or longer led to a suppression of distant metastases. The median survival time from the start of the treatment is 23+ months (range, 3-120+) for 12 patients with macroscopic and microscopic residual disease. The progression-free survival at 6 months was 75%. The combined treatment was associated with a low general toxicity, but attention must be given to increased normal tissue reactions. CONCLUSIONS: This trimodal treatment leads to excellent response rates, and it suppresses distant metastases when given as maintenance therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Drug Administration Schedule -
- Female -
- Hemangiopericytoma - drug therapy
- Hemangiosarcoma - drug therapy
- Humans - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Radiation-Sensitizing Agents - therapeutic use
- Radiotherapy Dosage - therapeutic use
- Razoxane - administration and dosage
- Vindesine - administration and dosage
- Find related publications in this database (Keywords)
- Angiosarcoma
- Antiangiogenic drugs
- Combined modality treatment
- Razoxane
- Vindesine